Teriflunomide Accord Европска Унија - Хрватски - EMA (European Medicines Agency)

teriflunomide accord

accord healthcare s.l.u. - teriflunomide - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivima selektivni imunosupresivima - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Degarelix Accord Европска Унија - Хрватски - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - prostatske neoplazme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

MST Continus 10 mg tablete s produljenim oslobađanjem Хрватска - Хрватски - HALMED (Agencija za lijekove i medicinske proizvode)

mst continus 10 mg tablete s produljenim oslobađanjem

mundipharma gesellschaft m.b.h., wiedner gurtel 13, turm 24, og 15, beč, austrija - morfinsulfat - tableta s produljenim oslobađanjem - 10 mg - urbroj: jedna tableta sadrži 10 mg morfinsulfata što odgovara 7,5 mg morfina

MST Continus 100 mg tablete s produljenim oslobađanjem Хрватска - Хрватски - HALMED (Agencija za lijekove i medicinske proizvode)

mst continus 100 mg tablete s produljenim oslobađanjem

mundipharma gesellschaft m.b.h., wiedner gurtel 13, turm 24, og 15, beč, austrija - morfinsulfat - tableta s produljenim oslobađanjem - 100 mg - urbroj: jedna tableta sadrži 100 mg morfinsulfata što odgovara 75 mg morfina

MST Continus 30 mg tablete s produljenim oslobađanjem Хрватска - Хрватски - HALMED (Agencija za lijekove i medicinske proizvode)

mst continus 30 mg tablete s produljenim oslobađanjem

mundipharma gesellschaft m.b.h., wiedner gurtel 13, turm 24, og 15, beč, austrija - morfinsulfat - tableta s produljenim oslobađanjem - 30 mg - urbroj: jedna tableta sadrži 30 mg morfinsulfata što odgovara 22,5 mg morfina

MST Continus 60 mg tablete s produljenim oslobađanjem Хрватска - Хрватски - HALMED (Agencija za lijekove i medicinske proizvode)

mst continus 60 mg tablete s produljenim oslobađanjem

mundipharma gesellschaft m.b.h., wiedner gurtel 13, turm 24, og 15, beč, austrija - morfinsulfat - tableta s produljenim oslobađanjem - 60 mg - urbroj: jedna tableta sadrži 60 mg morfinsulfata što odgovara 45 mg morfina

Lacosamide Adroiq Европска Унија - Хрватски - EMA (European Medicines Agency)

lacosamide adroiq

extrovis eu ltd. - lakozamida - epilepsija - antiepileptici sredstva, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Tivicay Европска Унија - Хрватски - EMA (European Medicines Agency)

tivicay

viiv healthcare bv - dolutegravir - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.

Adcetris Европска Унија - Хрватски - EMA (European Medicines Agency)

adcetris

takeda pharma a/s - Брентуксимаб ведотин - lymphoma, non-hodgkin; hodgkin disease - antineoplastična sredstva - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). Адцетриса indiciran za liječenje odraslih pacijenata s relaps ili vatrostalne cd30+ limfom Ходжкина (ЛХ):nakon terapije, orfollowing barem dva do terapije nakon terapije ili мультиагентной kemoterapije-to nije opcija liječenja . sistem анапластическая крупноклеточная lymphomaadcetris u kombinaciji s ciklofosfamid, doksorubicin i prednizon (chp) je prikazana za odrasle pacijente s prethodno liječenih liječenje sistemske анапластической veliki stanica limfoma (salcl). Адцетриса indiciran za liječenje odraslih pacijenata s relaps ili vatrostalne salcl. kožni t-stanica lymphomaadcetris indiciran za liječenje odraslih bolesnika s cd30+ stanica kožni t limfom (ctcl), nakon što je najmanje 1 do sistemske terapije.

Entyvio Европска Унија - Хрватски - EMA (European Medicines Agency)

entyvio

takeda pharma a/s - vedolizumab - colitis, ulcerative; crohn disease - selektivni imunosupresivi - colitisentyvio ulcerozni indiciran za liječenje odraslih bolesnika s вмеру na strogo aktivno язвенному колиту, koji su imali neadekvatan odgovor, izgubila odgovor, ili iz netrpeljivosti ili tradicionalne terapije ili faktor nekroze tumora alfa (Фноа) antagonist. diseaseentyvio kruna je indiciran za liječenje odraslih bolesnika s bolešću reumatoidnim kruna, koji su imali neadekvatan odgovor, izgubila odgovor, ili iz netrpeljivosti ili tradicionalne terapije ili faktor nekroze tumora alfa (Фноа) antagonist. pouchitisentyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.